McKesson Corporation (MCK) Financials
PeriodQ1 FY2027
Published
McKesson reported $105.38 billion in revenue for Q1 FY2027, the quarter ended June 30, 2026, up 7.7% from a year earlier, with gross profit of $3.69 billion, up 12.4%, and operating income of $1.32 billion, up 27.3%. Most of that operating income increase came from the absence of a prior-year bad-debt provision on the Rite Aid bankruptcy, which sat in selling, distribution, general and administrative expenses a year earlier. Net income attributable to McKesson fell to $614 million, down 21.7%, and diluted earnings per share to $5.15 from $6.25. McKesson attributes that decline principally to non-cash adjustments remeasuring redeemable noncontrolling interests to redemption value, the larger relating to the June 2026 sale of a minority stake in its Medical-Surgical Solutions business to funds managed by affiliates of Apollo Global Management and a smaller one to the Core Ventures business, items that sit below operating income. On the company's own adjusted basis, which excludes those remeasurements and other items, both operating profit and earnings per diluted share rose, and McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance range.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $105,380,000,000 | up 7.7% |
| Net income | $614,000,000 | down 21.7% |
| Diluted EPS | $5.15 | down 17.6% |
| Operating income | $1,319,000,000 | up 27.3% |
| Gross profit | $3,685,000,000 | up 12.4% |
Company details
| Name | Mckesson Corp |
|---|---|
| Ticker | MCK |
| CIK | 0000927653 |
| Exchange | NYSE |
| State | Texas |
| Incorporation | Delaware |
| SIC | 5122 |
| Office | Trade & Services |
| Industry | Wholesale-Drugs, Proprietaries & Druggists' Sundries |
| Latest period covered | Q1 FY2027, ended 2026-06-30, 10-Q, accession 0000927653-26-000234 |
| Fiscal year end | 03/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-05 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · McKesson Q1 FY2027
How much revenue did McKesson report in Q1 FY2027?
McKesson reported $105.38 billion in revenue for Q1 FY2027, the quarter ended June 30, 2026. That is up 7.7% from $97.83 billion in the same quarter a year earlier, driven by higher volumes in North American pharmaceutical distribution and by specialty growth in the Oncology and Multispecialty segment.
What was McKesson's earnings per share in Q1 FY2027?
McKesson reported diluted earnings per share of $5.15 for Q1 FY2027, the quarter ended June 30, 2026, down from $6.25 a year earlier. Net income attributable to McKesson was $614 million, down 21.7%.
Why did McKesson's profit fall in Q1 FY2027 even though revenue grew?
Net income attributable to McKesson fell to $614 million in Q1 FY2027, down 21.7%, principally because of non-cash adjustments remeasuring redeemable noncontrolling interests to redemption value, the larger relating to the June 2026 sale of a minority stake in its Medical-Surgical Solutions business and a smaller one to the Core Ventures business. Those adjustments sit below operating income and are absorbed in the earnings attributed to noncontrolling interests, which is what leaves less for McKesson even though operating income itself rose to $1.32 billion, up 27.3%.
What was McKesson's gross profit in Q1 FY2027?
McKesson earned gross profit of $3.69 billion on revenue of $105.38 billion in Q1 FY2027, the quarter ended June 30, 2026, the very thin spread characteristic of pharmaceutical wholesale distribution. Gross profit was up 12.4% from $3.28 billion a year earlier, growing faster than revenue, which was up 7.7%.
Where can I get McKesson Corporation (MCK) financial data in machine-readable form?
Ticker Scout publishes McKesson Corporation's financial statements as JSON at https://tickerscout.ai/mck/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/mck/narrative.md and https://tickerscout.ai/mck/events.md. McKesson Corporation's SEC CIK is 0000927653. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does McKesson Corporation (MCK) next file with the SEC?
McKesson Corporation (MCK) is expected to file its next Form 10-Q with the SEC on or around November 5, 2026. That date is a projection rather than a company-announced date: it is derived from McKesson Corporation's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q1 FY2027, the period ended 2026-06-30, SEC accession 0000927653-26-000234.
How this page was built
This page was built from McKesson Corporation's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names five such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.